Skip to main content

Table 1 Mean time in the therapeutic range observed in recent atrial fibrillation and venous thromboembolism randomized controlled trials of novel target oral anticoagulants

From: Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences

Study

Disease state

Mean TTR

TTR in month 1a

TTR in later monthsa

ARISTOTLE

NVAF

62 %

  

ENGAGE-TIMI-48 2013

NVAF

65 %

  

RE-LY 2009

NVAF

64 %

  

ROCKET-AF, 2010

NVAF

55 %

  

AMPLIFY

VTE

61 %

NR

NR

EINSTEIN-DVT

DVT

58 %

54 %

66 % (month 10)

EINSTEIN-PE

PE

63 %

58 %

73 % (month 11)

Hokusai-VTE

VTE

64 %

NR

NR

RECOVER 1

VTE

60 %

53 %

66 % (month 6)

RECOVER 2

VTE

57 %

51 %

54–62 % (months 3–6)

  1. DVT deep vein thrombosis, NR not reported, NVAF nonvalvular atrial fibrillation, PE pulmonary embolism, TTR time in the therapeutic range, VTE venous thromboembolism
  2. aFor venous thromboembolism studies only